Please assess the completion status of the following clinical trial:

Trial Title: A Study of Medication With or Without Psychotherapy for Complicated Grief

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Complicated Grief and this is the patient's most important (primary) problem~* Ability to give informed consent~* Fluent in English~* Willingness to have sessions audiotaped~* Willingness to undergo random assignment~Exclusion Criteria:~* Diagnosis of one or more of the following disorders: Schizophrenia or other psychotic disorder, current (past 6 months) substance abuse, Bipolar Disorder, current manic episode, Dementia~* Pregnant or lactating women and women of childbearing potential not using medically accepted forms of contraception~* Acute, unstable or severe medical illness such as (but not limited to) stroke, epilepsy, or other neurodegenerative disorders, metastatic or active cancer, hepatic disease, or primary renal disease requiring dialysis~* Prior intolerance of citalopram~* Pending or active disability claim or lawsuit related to the death

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- CGT with Citalopram (Type: ACTIVE_COMPARATOR): Targeted psychotherapy for complicated grief will be combined with SSRI medication.
- Citalopram (Type: ACTIVE_COMPARATOR): Citalopram is an Selective Serotonin Reuptake Inhibitor (SSRI) medication. It will be combined with grief-focused clinical management.
- Placebo (Sugar pill) (Type: PLACEBO_COMPARATOR): Inactive medication. It will be combined with grief-focused clinical management.
- CGT with Placebo (Type: ACTIVE_COMPARATOR): The targeted psychotherapy for complicated grief will be combined with inactive medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).